Is Assertio Holdings, Inc. (ASRT) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 52.9% / 30% | 133.0% / 30% | 72.0% / 30% | 2.58% / 5% | ✗ NOT HALAL |
| DJIM | 52.9% / 33% | 133.0% / 33% | 72.0% / 33% | 2.58% / 5% | ✗ NOT HALAL |
| MSCI | 14.0% / 33% | 35.1% / 33% | 19.0% / 33% | 2.58% / 5% | ✗ NOT HALAL |
| S&P | 52.9% / 33% | 133.0% / 33% | 72.0% / 33% | 2.58% / 5% | ✗ NOT HALAL |
| FTSE | 14.0% / 33% | 35.1% / 33% | 19.0% / 50% | 2.58% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 70.2% | |
| Operating Margin | -105.2% | |
| Net Margin | -25.6% | |
| Return on Equity (ROE) | -28.3% | |
| Return on Assets (ROA) | -3.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$28M |
| Free Cash Flow | -$28M |
| Total Debt | $40M |
| Debt-to-Equity | 42.8 |
| Current Ratio | 1.7 |
| Total Assets | $267M |
Price & Trading
| Last Close | $19.53 |
| 50-Day MA | $12.54 |
| 200-Day MA | $11.65 |
| Avg Volume | 58K |
| Beta | 0.8 |
|
52-Week Range
$7.65
| |
About Assertio Holdings, Inc. (ASRT)
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Assertio Holdings, Inc. (ASRT) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Assertio Holdings, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Assertio Holdings, Inc.'s debt ratio?
Assertio Holdings, Inc.'s debt ratio is 52.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 14.0%.
What are Assertio Holdings, Inc.'s key financial metrics?
Assertio Holdings, Inc. has a market capitalization of $125M, and revenue of $119M. The company maintains a gross margin of 70.2% and a net margin of -25.6%. Return on equity stands at -28.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.